Novo Nordisk: Oral Wegovy Go-to-Market Strategy
Summer 2025
The Challenge
The global anti-obesity medication market exceeded $30 billion in 2024, growing at 25%+ CAGR through 2032. Novo Nordisk's injectable semaglutide dominated the category, but the injection format blocked adoption for a large patient segment. Oral semaglutide offered the same efficacy in pill form: the OASIS trial program confirmed approximately 15% average weight loss over 68 weeks. The task was to build a go-to-market strategy for the U.S. launch.
- Oral formulations projected at 25-35% lower cost than injectables, supporting broader market access and global distribution scale (MBA 560 project research, 2025)
My Contribution
Five-person MBA 560 team project, Summer 2025. Primary contributions: 5Cs environmental analysis and the Product Marketing Program (Overall Marketing Program, Marketing Program Changes, Demand Generation, Branding Strategy, and Recommendations).
What I Built
The Product Marketing Program covered:
- Integrated launch strategy targeting needle-averse adults aged 25-55
- Digital-first channel architecture: YouTube, Instagram, Facebook, Google Ads with keyword targeting
- Influencer strategy: healthcare practitioners on TikTok and YouTube Shorts
- Traditional media: health TV channels, lifestyle magazines, pharmacy-adjacent billboard placements
- Experiential marketing: wellness expo activations and pop-up HCP Q&A sessions
- Content marketing: SEO-optimized blog posts, medical practitioner video series
- HCP communication updates: field rep training materials and side-by-side injectable vs oral comparison guides
- Branding strategy for Wegovy tablet positioning as convenient alternative, not injectable replacement
Key Findings
| Finding | Implication |
|---|---|
| 40-50% of obesity-eligible patients cite injection format as the primary barrier to treatment | Oral formulation expands the market rather than cannibalizing injectable revenue |
| PCPs require formulary access before prescribing new AOMs | Launch resources should target specialists first; PCP promotion activates after formulary milestones |
| 5Cs Context and competitive forces converge on a narrow 2026 U.S. launch window | Delay risks ceding first-mover advantage to Eli Lilly oral tirzepatide pipeline |
Tools Used
5Cs Analysis, SWOT, 4Ps, Competitor Analysis, Porter's Five Forces, Integrated Marketing Planning
How I'd Extend This
The next iteration adds primary payer research with PBMs and health plan medical directors to sharpen the formulary access recommendations. The analysis relied on public filings, and institutional negotiating behavior varies significantly by payer, so direct interviews would tighten the access strategy.
Bottom Line
The team delivered a full go-to-market framework for the oral semaglutide U.S. launch into a $30B+ AOM market growing at 25%+ CAGR. The Product Marketing Program set a digital-first channel architecture targeting needle-averse adults, backed by the finding that 40-50% of obesity-eligible patients cite injection format as their primary barrier, so the oral form expands the market rather than cannibalizing injectable revenue.